Dong, Mingfei
Telesca, Donatello
Sugar, Catherine
Shic, Frederick
Naples, Adam
Johnson, Scott P.
Li, Beibin
Atyabi, Adham
Xie, Minhang
Webb, Sara J.
Jeste, Shafali
Faja, Susan
Levin, April R.
Dawson, Geraldine
McPartland, James C.
Şentürk, Damla
,
Funding for this research was provided by:
National Institute of Mental Health (R01 MH122428, MH108206)
Article History
Received: 4 January 2022
Revised: 8 May 2022
Accepted: 25 July 2022
First Online: 5 September 2022
Declarations
:
: McPartland consults with Customer Value Partners, Bridgebio, Determined Health, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, and Springer. Dawson is on the Scientific Advisory Boards of Janssen Research and Development, Akili Interactive, Inc, LabCorp, Inc, Roche Pharmaceutical Company, and Tris Pharma, and is a consultant to Apple, Gerson Lehrman Group, Guidepoint Global, Inc, and is CEO of DASIO, LLC. Dawson has stock interests in Neuvana, Inc. Dawson has the following patent No. 10,912,801 and patent applications: 62,757,234, 25,628,402, and 62,757,226. Dawson has developed technology, data, and/or products that have been licensed to Apple, Inc. and Cryocell, Inc. and Dawson and Duke University have benefited financially. Shic consults for Roche Pharmaceutical Company, Janssen Research and Development, BlackThorn Therapeutics, and BioStream Technologies.